Publicacións nas que colabora con José María Ruiz Moreno (32)

2024

  1. Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain

    Ophthalmology and Therapy, Vol. 13, Núm. 7, pp. 1937-1953

  2. Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain

    Ophthalmology and Therapy, Vol. 13, Núm. 7, pp. 1925-1935

  3. Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

    Eye (Basingstoke)

  4. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database

    British Journal of Ophthalmology, Vol. 108, Núm. 2, pp. 253-262

  3. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

    The Lancet, Vol. 402, Núm. 10411, pp. 1434-1448

2022

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

  2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

    The Lancet, Vol. 399, Núm. 10326, pp. 741-755

2021

  1. Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study

    International Ophthalmology, Vol. 41, Núm. 10, pp. 3427-3436

2020

  1. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

2018

  1. Clinical decision-making when treating diabetic macular edema patients with dexamethasone intravitreal implants

    Ophthalmologica, Vol. 240, Núm. 2, pp. 61-72

2017

  1. Prevalence of Vitreoretinal Interface Abnormalities on Spectral-Domain OCT in Healthy Participants over 45 Years of Age

    Ophthalmology Retina

2016

  1. Reply

    Retina

2015

  1. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  2. Long-term outcomes of 23-gauge pars plana vitrectomy with internal limiting membrane peeling and gas tamponade for myopic traction maculopathy

    Retina, Vol. 35, Núm. 9, pp. 1836-1843

  3. Patología retiniana en alta miopía

    Sociedad Española de Oftalmología (SEO)

  4. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

2013

  1. Guías de tratamiento del desprendimiento de retina rhegmatógeno

    Archivos de la Sociedad Española de Oftalmologia, Vol. 88, Núm. 1, pp. 11-35